Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation

Not Applicable

Terminated

• Conditions: Congestive Heart Failure; Heart Failure; Cardiac Failure; Heart Failure, Left-sided
• Interventions: Device: Control VAD; Device: HeartAssist 5® VAD System

• Registration Number: NCT02205411
• Lead Sponsor: ReliantHeart Inc.

Brief Summary

The purpose of the study is to evaluate the safety and effectiveness of the ReliantHeart HeartAssist 5® VAD System in patients listed for heart transplantation and at risk of death from refractory end-stage heart failure.

Detailed Description

The HeartAssist 5® VAD System is intended for use as a bridge to heart transplantation and will be compared to the HeartMate II and HVAD devices.

Patients that meet the study criteria will be randomized 1:1 to either the HeartAssist 5® VAD System (treatment group) or control group (HeartMate II and HVAD). The physician will have the option to choose which control device to implant.

The primary objective of the study is to show non-inferiority of the HeartAssist 5® (treatment group) to the control group.

Study Timeline

• Study First Submitted: 2014-07-24
• Study First Submitted QC: 2014-07-29
• Study First Posted: 2014-07-31
• Study Start: 2014-09
• Status Verified: 2018-03
• Primary Completion: 2018-03
• Study Completion: 2018-03
• Last Update Submitted: 2018-07-16
• Last Update Posted: 2018-07-18

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

1. Able to sign Informed Consent.
2. Age ≥ 18
3. Body Surface Area (BSA) ≥ 1.2 m2.
4. Cardiac transplant candidate, defined as: Listed for cardiac transplant, and designated by the institution's multidisciplinary transplant committee as appropriate forLVAD Bridge-to-Transplantation therapy, or Designated by the institutions's multidisciplinary transplant committee as: 1) an appropriate candidate for LVAD Bridge-to transplant therapy, and 2) An inappropriate candidate for LVAD destination therapy
5. LVAD implantation has been approved by the institution's multidisciplinary transplant committee.
6. Patient is NYHA Class IV.
7. Able to return to the clinical site for all routine follow up visits.

Exclusion Criteria

1. Cardiothoracic surgery within 30 days prior to enrollment.
2. Acute Myocardial Infarction within 14 days prior to enrollment.
3. Prior cardiac transplantation, left ventricular reduction surgery, cardiomyoplasty or left ventricular assist device.
4. Mechanical, animal, or human tissue heart valve.
5. History of untreated abdominal or thoracic aortic aneurysm > 5 cm.
6. On ventilator support for > 72 hours within four days immediately prior to enrollment.
7. Ongoing mechanical circulatory support other than an intra-aortic balloon pump (IABP).
8. Proven history of pulmonary embolism within 90 days of enrollment.
9. Moderate to severe aortic insufficiency as determined by echocardiogram without plans for correction during pump implantation surgery.
10. Requires aortic, mitral, tricuspid or pulmonary valve replacements (including Bioprosthetic valves) or left ventricular (LV) aneurysm resection.
11. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelets <100,000, INR > 1.6 or PTT > 2.5 times control in the absence of anticoagulation therapy)
12. Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support OR extracorporeal membrane oxygenation (ECMO) at the time of implantation OR right atrial pressure > 20 mmHg while on multiple inotropes.
13. Significant renal dysfunction defined as > 3.5 mg/dl or requires hemo or peritoneal dialysis for renal failure (excluding ultra-filtration for fluid removal).
14. Evidence of intrinsic hepatic disease defined as liver enzyme values (AST, ALT and LDH that are > 3 times the upper limit of normal) OR a total bilirubin > 3 mg/dl OR biopsy proven liver cirrhosis or portal hypertension.
15. Pregnancy
16. Active systemic infection prior to study enrollment not yet resolved by treatment. Active Systemic Infection is defined by any one of the following in spite of antibiotic, antiviral or antifungal treatment: 2 or more consecutive positive cultures; elevated temperature > 37.2 (°C) and white blood cell count > 11.0 (103/ml); hypotension, tachycardia and generalized malaise.
17. Stroke within 90 days prior to enrollment OR patient has a history of cerebral vascular disease with > 80% extra cranial stenosis documented by carotid Doppler study during transplant evaluation
18. Modified Rankin Scale score of ≥ 2 or has any neurologic disability as confirmed by imaging (CT or MRI).
19. Significant lower extremity peripheral vascular disease accompanied by rest pain or leg ulceration.
20. Intolerant to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status.
21. Psychiatric disorder, or other psychosocial behavior that is likely to impair compliance with the study protocol.
22. Receiving therapy with an investigational intervention or participating in any other clinical investigation at the time of enrollment.
23. Condition, other than heart failure, that may limit survival to less than three (3) years and/or would exclude cardiac transplantation.
24. Unwilling or unable to comply with any study requirement.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control VAD	Control VAD	-
HeartAssist 5® VAD System	HeartAssist 5® VAD System	Implant of the HeartAssist 5® VAD System

Primary Outcome Measures

Name	Time	Method
The primary endpoint is success at 180 days	180 days	Success at 180 days is defined as alive on the original device, transplanted or explanted for heart recovery and alive 60 days after device explant.

Secondary Outcome Measures

Name	Time	Method
Adverse Events	180 days	Device safety will be reported as the frequency of each adverse event, (including device failure, device malfunction or unanticipated adverse device effects) and the rate of adverse events per patient year.
Quality of Life	180 days	Quality of life data, as measured by the EuroQol (EQ-5D) will be summarized and analyzed, for both groups, comparing data at baseline and study intervals.
Functional Status	180 days	NYHA and six-minute walk analysis will be reported by group for data at pre-implant and at study-defined intervals.
Neurologic Status	180 days	Evaluation of any change in Modified Rankin Scale from baseline to 180-days post-implant or device explant.

Trial Locations

Locations (14)

University of California San Francisco; 🇺🇸 San Francisco, California, United States

University of Stanford; 🇺🇸 Stanford, California, United States

University of Chicago Medical Center; 🇺🇸 Chicago, Illinois, United States

Indiana University Health, Inc. d/b/a Methodist Research Institute; 🇺🇸 Indianapolis, Indiana, United States

St. Vincent Hospital & Health Care Center; 🇺🇸 Indianapolis, Indiana, United States

Jewish Hospital; 🇺🇸 Louisville, Kentucky, United States

Mayo Clinic Hospital - Saint Mary's Campus; 🇺🇸 Rochester, Minnesota, United States

Minneapolis Heart Institute Foundation; 🇺🇸 Minneapolis, Minnesota, United States

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

CHI St. Luke's Baylor College of Medicine Medical Center; 🇺🇸 Houston, Texas, United States

University of Texas Health Science Center; 🇺🇸 Houston, Texas, United States

Houston Methodist Hospital; 🇺🇸 Houston, Texas, United States

Providence Sacred Heart Hospital; 🇺🇸 Spokane, Washington, United States

University of Miami; 🇺🇸 Coral Gables, Florida, United States